Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic value of nodal SUVmax of 18F-FDG PET/CT in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

  • Lee, So Jung (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kay, Chul-Seoung (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Yeon-Sil (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Son, Seok Hyun (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Myungsoo (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Sea-Won (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kang, Hye Jin (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2017.03.09
  • Accepted : 2017.06.30
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the predictive role of maximum standardized uptake value ($SUV_{max}$) of 2-[$^{18}F$]fluoro-2-deoxy-D-glucose($^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT). Materials and Methods: Between October 2006 and April 2016, 53 patients were treated with IMRT in two institutions and their PET/CT at the time of diagnosis was reviewed. The $SUV_{max}$ of their nasopharyngeal lesions and metastatic lymph nodes (LN) was recorded. IMRT was delivered using helical tomotherapy. All patients except for one were treated with concurrent chemoradiation therapy (CCRT). Correlations between $SUV_{max}$ and patients' survival and recurrence were analyzed. Results: At a median follow-up time of 31.5 months (range, 3.4 to 98.7 months), the 3-year overall survival (OS) and disease-free survival (DFS) rates were 83.2% and 77.5%, respectively. In univariate analysis, patients with a higher nodal pre-treatment $SUV_{max}$ (${\geq}13.4$) demonstrated significantly lower 3-year OS (93.1% vs. 55.5%; p = 0.003), DFS (92.7% vs. 38.5%; p < 0.001), locoregional recurrence-free survival (100% vs. 50.5%; p < 0.001), and distant metastasis-free survival (100% vs. 69.2%; p = 0.004), respectively. In multivariate analysis, high pre-treatment nodal $SUV_{max}$ (${\geq}13.4$) was a negative prognostic factor for OS (hazard ratio [HR], 7.799; 95% confidence interval [CI], 1.506-40.397; p = 0.014) and DFS (HR, 9.392; 95% CI, 1.989-44.339; p = 0.005). Conclusions: High pre-treatment nodal $SUV_{max}$ was an independent prognosticator of survival and disease progression in nasopharyngeal carcinoma patients treated with IMRT in our cohort. Therefore, nodal $SUV_{max}$ may provide important information for identifying patients who require more aggressive treatment.

Keywords

References

  1. Zhao W, Lei H, Zhu X, Li L, Qu S, Liang X. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensitymodulated radiotherapy: a retrospective analysis. Oncotarget 2016;7:86914-25.
  2. Guo Q, Lu T, Lin S, et al. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era. Jpn J Clin Oncol 2016;46:241-7. https://doi.org/10.1093/jjco/hyv192
  3. Luo Y, Gao Y, Yang G, Lang J. Clinical outcome and prognostic factors of intensity-modulated radiotherapy for T4 stage nasopharyngeal carcinoma. Biomed Res Int 2016;2016:4398498.
  4. Qiu WZ, Huang PY, Shi JL, Xia HQ, Zhao C, Cao KJ. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Chin J Cancer 2016;35:2. https://doi.org/10.1186/s40880-015-0076-9
  5. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238-44. https://doi.org/10.1016/S0360-3016(01)02781-X
  6. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163-71. https://doi.org/10.1016/S1470-2045(11)70320-5
  7. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in nonsmall-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6. https://doi.org/10.1200/JCO.1999.17.10.3201
  8. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998;82:2227-34. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO;2-W
  9. Lee SW, Nam SY, Im KC, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-dglucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008;87:211-6. https://doi.org/10.1016/j.radonc.2008.01.009
  10. Chan SC, Chang JT, Wang HM, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 2009;45:52-8. https://doi.org/10.1016/j.oraloncology.2008.03.010
  11. Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 2010;21:1078-82. https://doi.org/10.1093/annonc/mdp430
  12. Liu WS, Wu MF, Tseng HC, et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensitymodulated radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:561-6. https://doi.org/10.1016/j.ijrobp.2010.11.055
  13. Chan WK, Kwong DL, Yeung DW, Huang B, Khong PL. Prognostic impact of standardized uptake value of F-18 FDG PET/CT in nasopharyngeal carcinoma. Clin Nucl Med 2011;36:1007-11. https://doi.org/10.1097/RLU.0b013e31821a29a4
  14. Xiao W, Xu A, Han F, et al. Positron emission tomographycomputed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncol 2015;51:363-9. https://doi.org/10.1016/j.oraloncology.2015.01.009
  15. Jeong Y, Baek S, Park JW, Joo JH, Kim JS, Lee SW. Lymph node standardized uptake values at pre-treatment (18) F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma. Br J Radiol 2017;90:20160239. https://doi.org/10.1259/bjr.20160239
  16. Zhang J, Shu C, Song Y, Li Q, Huang J, Ma X. Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore) 2016;95:e5130. https://doi.org/10.1097/MD.0000000000005130
  17. Hui EP, Ma BB, Chan KC, et al. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer 2015;121:2720-9. https://doi.org/10.1002/cncr.29413
  18. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet 2016;387:1012-24. https://doi.org/10.1016/S0140-6736(15)00055-0
  19. Chan SC, Chang JT, Lin CY, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun 2011;32:989-96. https://doi.org/10.1097/MNM.0b013e3283495662
  20. Yang Z, Shi Q, Zhang Y, et al. Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol 2015;10:4. https://doi.org/10.1186/s13014-014-0268-5
  21. Inokuchi H, Kodaira T, Tachibana H, et al. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys 2011;79:747-55. https://doi.org/10.1016/j.ijrobp.2009.11.034
  22. Yoon YH, Lee SH, Hong SL, Kim SJ, Roh HJ, Cho KS. Prognostic value of metabolic tumor volume as measured by fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in nasopharyngeal carcinoma. Int Forum Allergy Rhinol 2014;4:845-50. https://doi.org/10.1002/alr.21363
  23. Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 2013;49:71-8. https://doi.org/10.1016/j.oraloncology.2012.07.016
  24. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of volumebased positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clin Exp Otorhinolaryngol 2015;8:142-8. https://doi.org/10.3342/ceo.2015.8.2.142
  25. Lin J, Xie G, Liao G, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:33884-96.